Search results
Independent pharmacies at disadvantage with franchise companies
Tahlequah Daily Press, Okla. via Yahoo News· 4 days agoJun. 10—High drug costs in the U.S. often prompt patients to order from other countries, and smaller rural and independent pharmacies suffer from requirements for sourcing ...
The 20 Countries Where People Buy the Most Cannabis
247wallst.com· 6 days agoAll the data for this list is taken from public filings from cannabis dispensaries. Cannabis is a banned substance in Croatia, with possession for...
These cannabis stocks have solid growth prospects - with help from the Biden administration
Morningstar· 6 days agoThe U.S. Department of Health and Human Services (HHS) has asked the U.S. Drug Enforcement Agency (DEA) and its parent the Department of Justice (DOJ) to reschedule cannabis ...
AP News Summary at 9:06 p.m. EDT
The Meridian Star· 3 days agoHunter Biden’s legal woes are not over after his conviction on three felony firearms charges in a trial that put a spotlight on his drug-fueled past. Jurors ...
Española tenants sue feds, apartment landlords
Santa Fe New Mexican· 7 days agoDepartment of Agriculture Secretary Thomas Vilsack, former owner Bosley Management Inc. and current owners Villas de Avenida Canada as defendants.
Troubled G7 leaders focus on Ukraine war, China in Italian summit
WHTC 1450 Holland· 2 days agoBy Crispian Balmer and Angelo Amante BARI, Italy (Reuters) - Group of Seven (G7) leaders start their...
Balyasny Asset Management L.P. Grows Holdings in Albertsons Companies, Inc. (NYSE:ACI)
ETF DAILY NEWS· 4 days agoBalyasny Asset Management L.P. grew its stake in Albertsons Companies, Inc. (NYSE:ACI – Free Report) by 25.9% during the fourth quarter, according to its most recent 13F filing with the SEC.
Charles River Laboratories International (NYSE:CRL) Upgraded to “Buy” by StockNews.com
ETF DAILY NEWS· 7 days agoUBS Group raised their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on ...
Celldex Therapeutics (NASDAQ:CLDX) Now Covered by Analysts at Wolfe Research
ETF DAILY NEWS· 4 days agoThe firm set an “outperform” rating and a $51.00 price target on the biopharmaceutical company’s stock. Wolfe Research’s price target would suggest a potential upside of 47.23% from the company ...
Schroder Investment Management Group Acquires 209,331 Shares of Intra-Cellular Therapies, Inc....
ETF DAILY NEWS· 6 days agoSchroder Investment Management Group increased its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 36.7% during the fourth quarter, according to its most recent Form ...